Authors:
Ibrahim, NK
Valero, V
Rahman, Z
Theriault, RL
Walters, RS
Buzdar, AU
Booser, DJ
Holmes, FA
Murray, DJ
Willey, J
Bast, R
Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I-II vinorelbine (Navelbine((R))) by continuous infusion in patientswith metastatic breast cancer: Cumulative toxicities limit dose escalation, CANCER INV, 19(5), 2001, pp. 459-466
Authors:
Ibrahim, NK
Valero, V
Theriault, RL
Willey, J
Walters, RS
Buzdar, AU
Booser, DJ
Hortobagyi, GN
Citation: Nk. Ibrahim et al., Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer, AM J CL ONC, 23(2), 2000, pp. 117-121
Authors:
Booser, DJ
Walters, RS
Holmes, FA
Hortobagyi, GN
Citation: Dj. Booser et al., Continuous-infusion high-dose leucovorin with 5-fluorouracil and cisplatinfor relapsed metastatic breast cancer: A phase II study, AM J CL ONC, 23(1), 2000, pp. 40-41
Authors:
Holmes, FA
Valero, V
Walters, RS
Theriault, RL
Booser, DJ
Gibbs, H
Fraschini, G
Buzdar, AU
Willey, J
Frye, D
Asmar, L
Hortobagyi, GN
Citation: Fa. Holmes et al., Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: Phase I results, ANN ONCOL, 10(4), 1999, pp. 403-411
Authors:
Valero, V
Buzdar, AU
Theriault, RL
Azarnia, N
Fonseca, GA
Willey, J
Ewer, M
Walters, RS
Mackay, B
Podoloff, D
Booser, D
Lee, LW
Hortobagyi, GN
Citation: V. Valero et al., Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, andfluorouracil as first-line therapy in patients with metastatic breast cancer, J CL ONCOL, 17(5), 1999, pp. 1425-1434